Economic evaluation of Abiraterone Acetate (Zytiga®) for the treatment of patients with metastatic castration-resistant prostate cancer (PRCP) who have received prior Docetaxel-based chemotherapy
ثبت نشده
چکیده
منابع مشابه
Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
Metastatic castration-resistant prostate cancer (mCRPC) with visceral involvement requires new, effective and safe treatments after chemotherapy failure. The CYP17A1 inhibitor abiraterone acetate has been approved as a treatment for mCRPC, both after docetaxel chemotherapy and more recently for patients who are not responding to chemotherapy. In published studies, most patients previously treat...
متن کاملA Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
OBJECTIVE In this Phase 2 multicenter study the efficacy and safety of oral abiraterone acetate (1000 mg/once daily) plus prednisolone (5 mg/twice daily) was evaluated in metastatic castration-resistant prostate cancer patients from Japan who had previously received docetaxel-based chemotherapy. METHODS Men (aged ≥20 years) with metastatic castration-resistant prostate cancer (prostate-specif...
متن کاملAbiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer.
INTRODUCTION Prostate cancer is the second most common cancer diagnosed in men living in the U.S. The disease was expected to account for more than 28,000 deaths in 2012,1 and more than 241,700 new cases were expected to be diagnosed that year.2 Prostate cancer usually affects men after the age of 40. Besides age, other risk factors include ethnicity, dietary practices, and genetic predispositi...
متن کاملCCR Perspectives in Drug Approval Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary
On December 10, 2012, the U.S. Food and Drug Administration granted full approval for a modified indication for abiraterone acetate (Zytiga tablets; Janssen Biotech, Inc.) in combinationwith prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The approval was based on clinical trial COU-AA-302, which randomly allocated asymptomatic or mildly sy...
متن کاملBudgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
BACKGROUND Abiraterone acetate, an androgen biosynthesis inhibitor, received FDA approval in 2011 for metastatic castration-resistant prostate cancer (mCRPC) patients who have received prior chemotherapy containing docetaxel. OBJECTIVE To estimate the projected budgetary impact of adopting abiraterone for mCRPC patients from a U.S. health plan perspective. METHODS A decision analytic model ...
متن کامل